Trial Profile

A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efdamrofusp alfa (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Adverse reactions
Sponsors Innovent Biologics

Most Recent Events

14 Nov 2021 According to an Innovent Biologics media release, results from this trial were released in e-poster at 2021 American Academy of Ophthalmology.
14 Nov 2021 Results published in an Innovent Biologics Media Release.
10 Nov 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com